Skip to content

293480.KS

Hana Pharm Co., Ltd.

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR

KRW 8,420.00
−1.17%
Ask drillr

Year over year

Reported trailing growth

Revenue
+7.5%
EBITDA
-34.5%
EBIT
+16.8%
EPS
-14.7%
Free cash flow
Operating cash flow
-33.7%

Forward estimates

Based on analyst estimates

Revenue
-46.1%
EBITDA
EPS

Three-year CAGR

Revenue
+4.3%
EBITDA
-0.7%
EBIT
-6.0%
Net income
-28.8%
EPS
-28.8%
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026